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 PGP variation was studied in 2 TCBZ resistant and 3 susceptible Latin 
American isolates 
 No SNPs in the terminal domain of PGP could be associated with TCBZ 
resistance 
 Several variable positions are detected along the 42 Kb of the FhPGP gene 
 More detailed and extensive efforts are needed to identify markers of resistance 
 
 
 
 
 
ABSTRACT 
The use of Triclabendazole for controlling fasciolosis is compromised by increased drug 
resistance affecting livestock and humans. Although the mode of action of TCBZ is still 
unknown, putative candidates and markers of resistance have been advanced. A single 
nucleotide polymorphism (T687G) in F. hepatica PGP was proposed as marker of 
resistance in a small scale study of European susceptible and resistant flukes, but the 
association was not found in Australian samples. The T687G SNP was absent in more 
than 40 samples from 2 TCBZ-resistant and 3 susceptible isolates across Latin America 
here analyzed. While the American samples showed more variable SNPs than the 
previous ones, none of the SNPs detected showed a marked association with resistance. 
Analyzing the 42 kb of the FhPGP gene based on RNAseq data highlights that the 
variation has been underestimated, suggesting that more detailed efforts are needed in 
order to identify markers of resistance.  
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Fasciolosis, is arguably one of the most widely distributed zoonotic diseases, with a  
major impact on livestock resulting in important economic losses estimated at thousands 
of millions  of dollars globally [1]. The increased incidence of human cases has drawn 
attention to this neglected foodborne disease affecting approximately 50 million people 
worldwide [2]. In the Americas the disease is widespread in livestock, while is considered 
an important human foodborne infection in the Altiplano region of Bolivia and Peru [3]. 
Triclabendazole (TCBZ) is the drug of choice to combat this parasite based on its broad 
spectrum of activity against liver fluke of all ages down to 2 days post-infection in the 
definitive host  [4]. However, the effectivity of this benzimidazolic drug has been 
compromised by reports of TCBZ resistance that first emerged in Australia, and were 
rapidly followed by cases in Europe, and in South America. More worrying, human cases 
reluctantly treated with TCBZ have been recently reported in Chile, and Peru (reviewed 
in [5]. 
Investigation of TCBZ resistance in the fluke in laboratories worldwide has resulted 
in the pursuit of a number of potential candidate genes and biological pathways [4,5]. The 
precise loci and, therefore, genes involved are still to be defined but a genome-wide 
approach is currently underway to identify the major genetic determinant of TCBZ 
resistance [6]. The increased cellular efflux of TCBZ in F. hepatica is related to ABC 
transporters as the P-glycoproteins (PGP) [4,7]. TCBZ-resistant isolates have been shown 
to process TCBZ more rapidly and their resistant phenotype can be reversed, under in 
vitro conditions, by the co-administration of inhibitors of P-glycoprotein (PGP) drug 
efflux pumps or drug detoxification pathways [4,8].  
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A previous study on European Fasciola isolates suggested that a single nucleotide 
polymorphism (SNPs) resulting in a PGP point mutation was associated with the resistant 
phenotype [9]. The same variation was not associated with resistance in Australian 
isolates [10]. In this study we analyzed the same terminal domain of F. hepatica PGP at 
the DNA and transcript levels in several samples with different status of resistance 
obtained from different locations across South America and compared them with those 
of the previous European and Australian studies. Our dataset consisted of individual 
flukes from 2 isolates defined as TCBZ-resistant from Bariloche, Argentina (7 samples) 
[11,12] and Cajamarca, Peru (10 DNA and 3 cDNA samples)  [12,13], 7 flukes from an 
Argentinian isolate (Cedive, Chascomus) susceptible to TCBZ but resistant to 
Albendazole (ABZ) [12,14]. Beside this we included a TCBZ-susceptible isolate from 
Mexico (6 DNA and 7 cDNA samples), and 13 individuals flukes from field isolates from 
Catamarca, Argentina whose resistant status is unknown (Suppl. Figure 1). As an 
additional reference for this study, 5 adult flukes of the UK Cullompton susceptible 
isolate were also analyzed [12].  Considering this study and the two previous ones, the 
geographical width of the analysis of PGP variation is extended and the total amount of 
resistant and susceptible worms analyzed is roughly doubled (Suppl. Figure 1, Table 1).   
We analyzed 16 variable positions in an amplimer of 830 bp, some of them shared 
with the previous studies and some novel. Eleven of the variable positions fall within the 
last intron, and the remaining 5 variable sites on the adjacent regions of the two final 
exons of PGP (Figure 1 B, C). All the American samples have an extra residue in a stretch 
of consecutive adenines within the intron that we noted here as position 352 indel. An 
extra base in this region was also reported in most of the samples from the Australian 
study [10], and is found in both available genome assemblies, and in 4 flukes of the 
European Cullompton isolate sequenced by us. Considering these differences we wonder 
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if the differences observed are due to a true indel or rather a differences in the base calling 
imposed by the presence of homopolymeric bases. 
Conserved characteristics of all Latin American samples are the presence of a G 
residue instead of a T in position 267, while the site is variable in European and Australian 
samples. Also an enrichment in T in intronic position 617 is observed in the American 
dataset (25 homozygous and 7 heterozygotes of 44 samples) in relation to the other 
datasets (12/24 and 9/24 in Australian and European samples respectively) 
(Supplementary Table 1 A). In general we detected more variability in the Latin American 
samples, particularly with the more frequent presence of heterozygous positions (25/43 
samples vs 7/20 [9] and 13/30 [10] in European and Australian samples respectively.  
Interestingly 11 individual flukes share the particular feature of being heterozygous at 3 
concurrent intronic positions (C132T, G181T, G323T). The reason for this heterozygotic 
enrichment is not clear. Despite the wide geographical variation and resistant status of the 
American samples none of them presented the T687G SNP originally described as 
possibly associated with resistance, ruling out its association with the phenotype.  
In order to gain further insights we organized the samples into haplotypes according 
to the various SNPs shared in the region amplified using DnaSP6 [15]. For this, we 
consider all the variants in the 2 previous studies [9,10] and those here obtained, resulting 
in 31 different haplotypes (Table 1).  The American samples are the most diverse with 17 
haplotypes present, compared to 10 in the European samples [9] and 7 in the Australian 
flukes [10]. The most frequent ones were shared, being haplotype FH02 [9] also present 
in the Australian study (referred as haplotype A) [10],  but absent in America. Also highly 
abundant is haplotype 15 originally described as haplotype B by [10],   that is shared 
between Australian and American samples. In any case no clear association emerged 
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between the diverse haplotypes and the resistant status, despite their differential 
distribution.  
Since some of the intronic variations frequent in resistant flukes (particularly A617T) 
might result in a novel splicing acceptor site that would produce a longer final exon, we 
evaluated the presence of alternative splicing. RT-PCR performed on samples from 
susceptible and resistant isolates worms produced consistently a single band 
corresponding to the canonical predicted splicing site rather than two products differing 
by 45 bp, ruling out the possibility of alternative splicing (Supplementary Table 1 A). 
Since we have recently performed a transcriptomic analysis of 3 American isolates 
with different drug susceptibility [16], we looked at variations detected in the FhPGP 
gene in this study. We retrieved Contig 2471 where FhPGP is found and all the reads 
mapped to it from the three isolates, namely Cajamarca, Peru (TCBZR), Cenapa, Mexico 
(TCBZS) and Rubino, Uruguay (TCBZS, ABZR) [12]. SNPs were called based on the 
reference genome [17] using the Basic Variant tools of the CLC software package using 
default parameters. Despite only 2 individual flukes were analyzed from each isolate, 
several variable sites were found distributed in the 42 kb that comprises the PGP gene, 
most of them within several of the 18 exons (Figure 1 C, Supplementary Table 2). The 
low amount of samples analyzed do not allow to infer selective presence of SNPs in 
resistant or susceptible isolates. However, it is worth mention that most variants are 
shared. These results highlight that sequence variability can be high within F. hepatica as 
it has been advanced by the genomic studies [17,18]. Consequently efforts to associate 
variant sites with particular phenotypes as drug resistance need to be very cautious before 
reporting. 
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In conclusion our data confirm that the T687G SNP in the PGP gene alleged as 
candidate for TCBZ resistance marker [9] is not detected in any of the American 
sequences analyzed compromising its proposed involvement in TCBZ resistance.  Several 
other variable positions mapping within the last intron can be observed, but there is no 
evidence of altered splicing that might account for the resistant phenotype according to 
our RT-PCR experiments. Our study also highlight that the American isolates are slightly 
more variable at the PGP gene region under study than the European or Australian 
counterparts. This might be related to the largest dataset here analyzed and the fact that 
correspond to a widest geographical distribution of the Latin American samples.   These 
results are also consistent with recent descriptions of genetic variability in F. hepatica in 
general [18]. Interestingly a recent study showed low genetic diversity in Peruvian flukes 
from Cajamarca wen analyzing mitochondrial ND1 gene and the ribosomal ITS [19]. 
While these results compromise the causal role of the previously indicated SNP, they do 
not exclude PGP as a candidate to resistance. Indeed, the region studied so far represent 
less than a tenth of the original protein, and our transcriptomic evidence [16] show that 
much variation exist along the 42 kb of the gene. Furthermore, the genomic sequences of 
F.hepatica have revealed multiple ABC transporters that might be playing a detoxifying 
role. The availability of genomic sequences allow now to perform more extensive studies 
analyzing in parallel variations in several genes across numerous individuals, opening  
new avenues for investigating variants associated with the resistance of F. hepatica to 
TCBZ.  
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Figure Legends  
Figure 1.  (A) SNPs detected by genomic and RT PCR in different South American 
isolates. The PCR primer set (forward: TTGGTGTTGTATCGCAGGAA; reverse: 
AGCCGAAGTAGCTTCATCCA) amplified the second nucleotide binding domain of 
the PGP gene as described [9]. An amplification product of 830 bp (green bar in figure) 
was obtained when amplifying from genomic DNA, due to the presence of a 569 bp intron 
(yellow line, with boxes representing adjacent exons), and a shorter product of the 
expected size was obtained from RT-PCR reactions. Fragments were sequenced at 
Macrogen, Korea. Sequences were CAP aligned to the reference PGP gene in the two F. 
hepatica genome assemblies available [17,20]. In order to facilitate comparisons, we 
numbered variable positions according to PCR fragment position following the original 
report [9], and their relative position is indicated in the figure. Haplotypes were derived 
using DNASP6 [15]. Since we don’t know the phases in heterozygous positions, those 
were encoded with IUPAC consensus bases (i.e. R for G/A) and used as input for the 
program to estimate the haplotypes. Similarly the data from previous studies  [10] were 
included for comparison. The genotypes of all the samples are presented in 
Supplementary Table 1 and the resulting haplotypes are reported in Table 1. Sequences 
were deposited at GenBank (accessions MH267603-MH267660) (B). SNPs detected in 
PGP gene by RNAseq in three different South American isolates. RNA extracted from 
two individual worms each of the Cajamarca, Peru (TCBZR-ABZR), Rubino, Uruguay 
(TCBZS ABZR) and Cenapa, Mexico (TCBZS ABZS) isolates were used to generate 
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Illumina PE- RNAseq libraries. The resulting sequencing data was quality trimmed and 
mapped to the F.hepatica genome [17] with the CLC Genomics Workbench package 
(Qiagen, Aarhus A/S) as described [16]. For variant calling, we retrieved the contig 2471 
where FhPGP is found and all the reads that mapped to it from the three isolates analyzed. 
SNPs were called using the Variant tools of the CLC software package with default 
parameters (minimum coverage 10, minimum frequency 20%). The scheme represents 
the genomic structure of the FhPGP gene (BN1106_s2471B000078, on reverse strand) 
depicted in yellow in the top panel, with the region analyzed by PCR indicated (green 
box). RNAseq coverage on the Cajamarca (TCBZR, red dot) Cenapa, (TCBZS, green 
dot) and Rubino (ABZR, TCBZS, orange dot) isolates are indicated by blue peaks in 
independent tracks. SNPs variants detected along the whole coding region in each isolate 
are indicated as red bars at the bottom of each read map and detailed in Supplementary 
Table 2. Total reads and variants counted on the region are indicated on the track labels. 
RNAseq data was deposited as raw data at the SRA database under accession 
PRJNA339158. 
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 Table 1. Haplotypes found in this study (shaded) and in previous reports. 
Haplotypes generated by DnaSP6 [15] based on data obtained in this study (gray shaded) and in previous studies [9, 10]. Haplotype 1 of Wilkinson et al. [9] was taken as reference (Haplotype 
H02 of this study), and the variants detected are resumed in 2nd column, and detailed by position in the following columns. Those SNPs corresponding to exons are shaded. The total count of 
each haplotype, and their presence in sensitive and resistant individuals from different populations is resumed in the second part of the table (#).  Some alternative haplotypes for genotypes 
already described were predicted in this study and are indicated (*).   The correlation of the haplotypes names between this study and the previous ones is indicated in the last column. 
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AC
CE
PT
ED
 M
AN
US
CR
IPT
